D Tomlinson1, P D Robinson2, S Oberoi2, D Cataudella3, N Culos-Reed4, H Davis1, N Duong1, F Gibson5, M Götte6, P Hinds7, S L Nijhof8, P van der Torre8, S Cabral2, L L Dupuis1,9, L Sung1,10. 1. Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON. 2. Pediatric Oncology Group of Ontario, Toronto, ON. 3. Department of Pediatric Psychology, Children's Hospital, London Health Sciences Centre, London, ON. 4. Faculty of Kinesiology, University of Calgary, Calgary, AB. 5. Centre for Outcomes and Experiences Research in Children's Health, Illness, and Disability, Great Ormond Street Hospital for Children NHS Foundation Trust, London, and School of Health Sciences, University of Surrey, Guildford, U.K. 6. University Hospital Essen, Center for Child and Adolescent Medicine, Department of Pediatric Hematology/Oncology, Essen, Germany. 7. Department of Nursing Science, Professional Practice, and Quality, Children's National Health System; and Department of Pediatrics, George Washington University, Washington, DC, U.S.A. 8. Division of Pediatrics, Wilhelmina Children's Hospital (part of UMC Utrecht), Utrecht, Netherlands. 9. Department of Pharmacy, The Hospital for Sick Children; and Leslie Dan Faculty of Pharmacy, University of Toronto, The Hospital for Sick Children, Toronto, ON. 10. Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, ON.
Abstract
Background: Our objective was to determine whether, compared with control interventions, pharmacologic interventions reduce the severity of fatigue in patients with cancer or recipients of hematopoietic stem-cell transplantation (hsct). Methods: For a systematic review, we searched medline, embase, the Cochrane Central Register of Controlled Trials, cinahl, and Psychinfo for randomized trials of systemic pharmacologic interventions for the management of fatigue in patients with cancer or recipients of hsct. Two authors independently identified studies and abstracted data. Methodologic quality was assessed using the Cochrane Risk of Bias tool. The primary outcome was fatigue severity measured using various fatigue scales. Data were synthesized using random-effects models. Results: In the 117 included trials (19,819 patients), the pharmacologic agents used were erythropoietins (n = 31), stimulants (n = 19), l-carnitine (n = 6), corticosteroids (n = 5), antidepressants (n = 5), appetite stimulants (n = 3), and other agents (n = 48). Fatigue was significantly reduced with erythropoietin [standardized mean difference (smd): -0.52; 95% confidence interval (ci): -0.89 to -0.14] and with methylphenidate (smd: -0.36; 95% ci: -0.56 to -0.15); modafinil (or armodafinil) and corticosteroids were not effective. Conclusions: Erythropoietin and methylphenidate significantly reduced fatigue severity in patients with cancer and in recipients of hsct. Concerns about the safety of those agents might limit their usefulness. Future research should identify effective interventions for fatigue that have minimal adverse effects.
Background: Our objective was to determine whether, compared with control interventions, pharmacologic interventions reduce the severity of fatigue in patients with cancer or recipients of hematopoietic stem-cell transplantation (hsct). Methods: For a systematic review, we searched medline, embase, the Cochrane Central Register of Controlled Trials, cinahl, and Psychinfo for randomized trials of systemic pharmacologic interventions for the management of fatigue in patients with cancer or recipients of hsct. Two authors independently identified studies and abstracted data. Methodologic quality was assessed using the Cochrane Risk of Bias tool. The primary outcome was fatigue severity measured using various fatigue scales. Data were synthesized using random-effects models. Results: In the 117 included trials (19,819 patients), the pharmacologic agents used were erythropoietins (n = 31), stimulants (n = 19), l-carnitine (n = 6), corticosteroids (n = 5), antidepressants (n = 5), appetite stimulants (n = 3), and other agents (n = 48). Fatigue was significantly reduced with erythropoietin [standardized mean difference (smd): -0.52; 95% confidence interval (ci): -0.89 to -0.14] and with methylphenidate (smd: -0.36; 95% ci: -0.56 to -0.15); modafinil (or armodafinil) and corticosteroids were not effective. Conclusions: Erythropoietin and methylphenidate significantly reduced fatigue severity in patients with cancer and in recipients of hsct. Concerns about the safety of those agents might limit their usefulness. Future research should identify effective interventions for fatigue that have minimal adverse effects.
Authors: Maud M Geenen; Mathilde C Cardous-Ubbink; Leontien C M Kremer; Cor van den Bos; Helena J H van der Pal; Richard C Heinen; Monique W M Jaspers; Caro C E Koning; Foppe Oldenburger; Nelia E Langeveld; Augustinus A M Hart; Piet J M Bakker; Huib N Caron; Flora E van Leeuwen Journal: JAMA Date: 2007-06-27 Impact factor: 56.272
Authors: Brian Leyland-Jones; Vladimir Semiglazov; Marek Pawlicki; Tadeusz Pienkowski; Sergei Tjulandin; George Manikhas; Antoly Makhson; Anton Roth; David Dodwell; Jose Baselga; Mikhail Biakhov; Konstantinas Valuckas; Edouard Voznyi; Xiangyang Liu; Els Vercammen Journal: J Clin Oncol Date: 2005-08-08 Impact factor: 44.544
Authors: Andrew J Roth; Christian Nelson; Barry Rosenfeld; Howard Scher; Susan Slovin; Michael Morris; Noelle O'Shea; Gabrielle Arauz; William Breitbart Journal: Cancer Date: 2010-11-01 Impact factor: 6.860
Authors: L S Young; R Bye; M Scheltinga; T R Ziegler; D O Jacobs; D W Wilmore Journal: JPEN J Parenter Enteral Nutr Date: 1993 Sep-Oct Impact factor: 4.016
Authors: Anna Spathis; Kate Fife; Fiona Blackhall; Susan Dutton; Ronja Bahadori; Rose Wharton; Mary O'Brien; Patrick Stone; Tim Benepal; Nick Bates; Bee Wee Journal: J Clin Oncol Date: 2014-04-28 Impact factor: 44.544
Authors: Jennifer S Mascaro; Alessia V Waller; Laurie Wright; Terri Leonard; Carla Haack; Edmund K Waller Journal: Integr Cancer Ther Date: 2019 Jan-Dec Impact factor: 3.279
Authors: E Anne Lown; Anu Banerjee; Eric Vittinghoff; Christopher C Dvorak; Wendy Hartogensis; Alexis Melton; Christina Mangurian; Hiroe Hu; Deborah Shear; Robyn Adcock; Michael Morgan; Carla Golden; Frederick M Hecht Journal: Glob Adv Health Med Date: 2019-08-14
Authors: Austin L Brown; Pagna Sok; Olga Taylor; John P Woodhouse; M Brooke Bernhardt; Kimberly P Raghubar; Lisa S Kahalley; Philip J Lupo; Marilyn J Hockenberry; Michael E Scheurer Journal: J Pain Symptom Manage Date: 2020-09-01 Impact factor: 3.612
Authors: Kelly E Rentscher; Judith E Carroll; Mark B Juckett; Christopher L Coe; Aimee T Broman; Paul J Rathouz; Peiman Hematti; Erin S Costanzo Journal: J Natl Cancer Inst Date: 2021-10-01 Impact factor: 13.506